Valuation dashboard for Adial Pharmaceuticals, Inc. (ADIL) with P/E N/A, P/B 155.24, EV/EBITDA 0.38 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $5.24, ADIL has negative trailing earnings (P/E not meaningful) and an ROE of -16.93%. Market capitalisation stands at $5M.
Balance sheet quality for ADIL: current ratio of 4.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 155.24 |
| EV / EBITDA | 0.38 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $7.97 |
| vs Current Price | +52.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADIL | Adial Pharmaceuticals, Inc. | $5M | 155.24 | -16.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $5.24 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -1693.21% |
| Return on Invested Capital | -240.64% |
| Return on Assets | -198.70% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · APRE · BCDA · BCLI · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ADIL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks